Loading clinical trials...
Loading clinical trials...
A Phase 0/I Study to Assess the Safety and Tolerability of XRD-0394 in Combination With Radiation Therapy in Patients With High Grade Gliomas
Conditions
Interventions
XRD-0394
Radiation Therapy
+1 more
Locations
1
United States
NYU Langone Health
New York, New York, United States
Start Date
November 5, 2025
Primary Completion Date
May 1, 2027
Completion Date
May 1, 2031
Last Updated
January 2, 2026
NCT06624371
NCT06660056
NCT06763965
NCT07472790
NCT04482933
NCT04552756
Lead Sponsor
NYU Langone Health
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions